# Terufumi Kato

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/terufumi-kato/

## Facts

| Field | Value |
| --- | --- |
| Citations | 30,632 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 58 |
| i10-index | 175 |
| Last Known Institution | Kanagawa Prefectural Hospital Organization |
| OpenAlex ID | https://openalex.org/A5091073688 |
| ORCID iD | https://orcid.org/0000-0002-5853-1424 |
| Works | 521 |

## Researcher papers

Showing 12 of 14.

- [Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-for-squamous-non-small-cell-lung-cancer/)
- [Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations](https://scholariq.org/papers/phase-iii-study-of-afatinib-or-cisplatin-plus-pemetrexed-in-patients-with/)
- [Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation](https://scholariq.org/papers/sotorasib-for-lung-cancers-with-i-kras-i-p-g12c-mutation/)
- [Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-resected-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials](https://scholariq.org/papers/afatinib-versus-cisplatin-based-chemotherapy-for-egfr-mutation-positive-lung/)
- [Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer](https://scholariq.org/papers/perioperative-pembrolizumab-for-early-stage-non-small-cell-lung-cancer/)
- [Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations](https://scholariq.org/papers/tepotinib-in-non-small-cell-lung-cancer-with-i-met-i-exon-14-skipping-mutations/)
- [Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study](https://scholariq.org/papers/erlotinib-alone-or-with-bevacizumab-as-first-line-therapy-in-patients-with/)
- [Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-resected-i-egfr-i-mutated-nsclc/)
- [Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-erlotinib-in-patients-with-untreated-egfr-mutated-advanced-non/)
- [Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial](https://scholariq.org/papers/four-year-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc-an/)
- [Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial](https://scholariq.org/papers/adjuvant-osimertinib-for-resected-egfr-mutated-stage-ib-iiia-non-small-cell-lung/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Kanagawa Prefectural Hospital Organization](https://scholariq.org/institutions/kanagawa-prefectural-hospital-organization/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.